Suppr超能文献

鉴定分枝杆菌核糖体蛋白作为 CD4 T 细胞的靶点,增强结核病的保护性免疫。

Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis.

机构信息

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.

Department of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.

出版信息

Infect Immun. 2018 Aug 22;86(9). doi: 10.1128/IAI.00009-18. Print 2018 Sep.

Abstract

remains a threat to global health, and a more efficacious vaccine is needed to prevent disease caused by We previously reported that the mycobacterial ribosome is a major target of CD4 T cells in mice immunized with a genetically modified strain (IKEPLUS) but not in mice immunized with BCG. Two specific ribosomal proteins, RplJ and RpsA, were identified as cross-reactive targets of , but the breadth of the CD4 T cell response to ribosomes was not determined. In the present study, a library of ribosomal proteins and -predicted peptide libraries were used to screen CD4 T cell responses in IKEPLUS-immunized mice. This identified 24 out of 57 ribosomal proteins distributed over both large and small ribosome subunits as specific CD4 T cell targets. Although BCG did not induce detectable responses against ribosomal proteins or peptide epitopes, the ribosomal protein RplJ produced a robust and multifunctional Th1-like CD4 T cell population when administered as a booster vaccine to previously BCG-primed mice. Boosting of BCG-primed immunity with the RplJ protein led to significantly reduced lung pathology compared to that in BCG-immunized animals and reductions in the bacterial burdens in the mediastinal lymph node compared to those in naive and standard BCG-vaccinated mice. These results identify the mycobacterial ribosome as a potential source of cryptic or subdominant antigenic targets of protective CD4 T cell responses and suggest that supplementing BCG with ribosomal antigens may enhance protective vaccination against .

摘要

结核分枝杆菌仍然是全球健康的威胁,需要更有效的疫苗来预防由结核分枝杆菌引起的疾病。我们之前报道过,在经基因修饰的结核分枝杆菌菌株(IKEPLUS)免疫的小鼠中,分枝杆菌核糖体是 CD4 T 细胞的主要靶点,但在经卡介苗(BCG)免疫的小鼠中则不是。两种特定的核糖体蛋白,RplJ 和 RpsA,被鉴定为交叉反应的结核分枝杆菌靶点,但 CD4 T 细胞对核糖体的反应广度尚未确定。在本研究中,使用核糖体蛋白文库和 -预测肽文库筛选 IKEPLUS 免疫小鼠中的 CD4 T 细胞反应。这确定了 57 种核糖体蛋白中的 24 种,它们分布在大亚基和小亚基上,是特定的 CD4 T 细胞靶点。虽然 BCG 没有诱导针对核糖体蛋白或肽表位的可检测反应,但当作为佐剂疫苗给予先前 BCG 免疫的小鼠时,核糖体蛋白 RplJ 产生了强大的多功能 Th1 样 CD4 T 细胞群。用 RplJ 蛋白增强 BCG 免疫的免疫力,与 BCG 免疫动物相比,肺病理学显著降低,与未感染和标准 BCG 疫苗接种的小鼠相比,纵隔淋巴结中的细菌负荷降低。这些结果表明,分枝杆菌核糖体可能是保护性 CD4 T 细胞反应的隐匿或亚显性抗原靶标的潜在来源,并表明用核糖体抗原补充 BCG 可能增强针对结核分枝杆菌的保护性疫苗接种。

相似文献

引用本文的文献

5
Vaccines against Tuberculosis: Where Are We Now?抗结核疫苗:我们目前的进展如何?
Vaccines (Basel). 2023 May 22;11(5):1013. doi: 10.3390/vaccines11051013.

本文引用的文献

6
Mycobacterium tuberculosis infection and vaccine development.结核分枝杆菌感染与疫苗研发
Tuberculosis (Edinb). 2016 May;98:30-41. doi: 10.1016/j.tube.2016.02.005. Epub 2016 Feb 27.
8
Status of vaccine research and development of vaccines for tuberculosis.结核病疫苗的研发现状
Vaccine. 2016 Jun 3;34(26):2911-2914. doi: 10.1016/j.vaccine.2016.02.079. Epub 2016 Mar 11.
9
Reprogramming the T Cell Response to Tuberculosis.重新编程T细胞对结核病的反应。
Trends Immunol. 2016 Feb;37(2):81-83. doi: 10.1016/j.it.2015.12.009. Epub 2016 Jan 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验